Cellular Therapies and Regenerative Medicine Strategies for Treatment of Diabetes
Camillo Ricordi, Stacy Joy Goodman Professor of Surgery; Distinguished Professor of Medicine; Director, Diabetes Research Institute and Cell Transplant Program, University of Miami
Camillo Ricordi is Professor and Director of the Diabetes Research Institute (DRI; www.diabetesresearch.org ) and the Cell Transplant Program at the University of Miami.
Dr. Ricordi and collaborators developed the method for large scale production of human pancreatic islets, and he led the team that performed the first series of successful clinical islet allotransplants to reverse diabetes. The procedure is now used by laboratories performing clinical islet transplants worldwide. Ricordi was president of the Cell Transplant Society, on the NIH-NIAID Expert Panel on clinical approaches for tolerance induction, on the FDA Biologic Response Modifiers Advisory Committee and on the NIH-NIDDK Strategic Planning Committee. Ricordi is currently serving as Chairperson of the NIH funded Clinical Islet Transplantation (CIT) Consortium, which standardized cell manufacturing protocols in North America and Europe and just completed the first multicenter FDA Phase III trial for what could become the first biologically active cell product approved in the US by the FDA.
Ricordi has received numerous honors and awards and was also Knighted by the President of the Republic of Italy. He is currently serving on the editorial boards of CellR4 (Editor-in-Chief; www.cellr4.org) and Cell Transplantation (Co-Editor-in-Chief). In 2013 he was appointed President of the Ri.MED Foundation by the Italian Prime Minister (www.fondazionerimed.eu), one of the largest European investments in Biomedical Research, Biotechnologies and Regenerative Medicine. Ricordi also serves as President of The Cure Alliance (www.thecurealliance.org) and Chairman of the Diabetes Research Institute Federation (www.diabetesresearch.org). He has authored over 700 scientific publications and 19 awarded patents.